Overexpression of Pim-1 in bladder cancer
- Shengjie Guo†1,
- Xiaopeng Mao†1,
- Junxing Chen1,
- Bin Huang1,
- Chu Jin2, 3,
- Zhenbo Xu2, 4 and
- Shaopeng Qiu1Email author
© Guo et al; licensee BioMed Central Ltd. 2010
Received: 12 November 2010
Accepted: 11 December 2010
Published: 11 December 2010
Pim-1 is a serine-threonine kinase which promotes early transformation, cell proliferation and cell survival during tumorigenesis. Several studies have demonstrated that Pim-1 kinase play a role in different cancer types, however, the function of Pim-1 in bladder cancer is poorly understood.
Expression and localization of Pim-1 in human normal and malignant bladder specimens were examined by Immunohistochemistry and Pim-1 staining score was compared with several clinicopathologic parameters. To further demonstrate the biological function of Pim-1 in bladder cancer, its expression was validated in five bladder cancer cell lines by western blot and immunohistochemistry analyses. Subsequent knockdown of Pim-1 was achieved by lentivirus encoding small interfering RNA, and the effect of Pim-1 on bladder cell survival and drug sensitivity were further assessed by colony formation and cell proliferation assays.
When compared with normal epithelium, Pim-1 was overexpressed in bladder cancer epithelium, and the expression level was higher in invasive bladder cancer than Non-invasive bladder cancer specimens. Pim-1 was also detected in all the bladder cancer cell lines examined in our study. Moreover, the knockdown of Pim-1 significantly inhibited bladder cancer cell growth and also sensitized cells to chemotherapeutic drugs in vitro.
Our results in this study suggest that Pim-1 may play a role in bladder cancer initiation and progression. Since Pim-1 is also involved in bladder cancer cell survival and drug resistance, Pim-1 is a potential candidate for targeted therapy in bladder cancer.
Bladder cancer is one of the most common types of cancer globally, with approximately 75% of the diagnosed tumors classified as Non-invasive tumor (Ta, Tis, or T1). Treatment of Non-invasive tumor includes transurethral resection (TUR) with or without intravesical instillation therapy, but the recurrence rate is high, ranging from 50% to 70%. In addition, an average of 10% to 20% for Non-invasive tumors may further progress to muscle-invasive disease, thus lead to eventual radical Cystectomy and urinary diversion [1–3]. In this context, clinicians face challenges to identify the novel therapeutic targets for bladder cancer.
Pim-1 is overexpressed in several types of cancer, including lymphoid and haematopoietic malignancies , prostate cancer , squamous cell carcinomas , gastric carcinoma and colorectal carcinomas . Currently available studies have demonstrated that the expression of Pim-1 can be predictive of tumor outcome following chemotherapy and surgery, and it is correlated with the enhanced metastatic potential of the tumor. As a member of serine/threonine kinase family, Pim-1 has multiple roles in tumorigenesis such as promoting transformation and cell proliferation partly through regulation of cell cycle and transcription by phosphorylating of number of substrates including cdc25A/C, HP1, and p100 [9–11]. Moreover, it has been shown that Pim-1 may play a role in the regulation of the survival signaling through the modulation of Bcl-2 family member including Bad, Bcl-2 and Bcl-XL [12–14]. However, the expression and significance of Pim-1 in bladder cancer remains unknown. Therefore, the aims of the present study are to investigate the expression level of Pim-1 in bladder cancer tissue and study its function in the pathogenesis and progression of bladder cancer.
Sixty-six clinical bladder samples isolated from the First Affiliated Hospital of the Sun Yat-Sen University (Guangzhou, China), were examined in the present study. All patients including forty-eight men (72.3%) and eighteen women (27.7%), had been treated for urothelial carcinoma of the bladder by transurethral resection of bladder (TUR) or Cystectomy and were diagnosed with a bladder cancer for the first time at an average age of 56 years (range, 33-78 years). Pathologic staging and grading were performed according to the 2002 TNM classification system and World Health Organization criteria, respectively. The use of the human tissue in this study was approved by the Ethics Council of the Sun Yat-Sen University for Approval of Research Involving Human Subjects.
All 5μm thick paraffin sections were deparaffinized with xylene and rehydrated through graded alcohol washes, followed by antigen retrieval by heating sections in sodium citrate buffer (10 mmol/L, pH6.0) for 30 minutes. Endogenous peroxidase activity was blocked with 30 min incubation in 0.03% H2O2 in methanol. The slides were then blocked by incubation in normal goat serum (dilution 1:10) in PBS (pH 7.4) and subsequently incubated for monoclonal mouse IgG1 anti-Pim-1 antibody(sc-13513; Santa Cruz Biotechnology, Santa Cruz, CA, USA) with 1:30 dilution at 4°C overnight. Following this step, slides were treated with biotin-labeled anti-IgG and incubated with preformed avidin-biotin peroxidase complex. Control staining of the same sections was performed with the preimmune primary antibody, and no Pim-1 immunostaining was observed in these sections. The sections were briefly counter-stained with hematoxylin. IHC reactions for all samples were repeated at least three times, and typical results were illustrated.
Scoring and Statistical analyses
The staining of Pim-1 was graded in each sample based on the intensity of the immunoreactivity in the cancer cells and was stratified as strong staining (3), moderate staining (2), weak staining (1) and negative (0). Using these criteria, the immunostaining results were evaluated independently by XPM and BH. The correlation of interobserver was calculated from the independent evaluations. For cases with discrepancy, a consensus was reached during a common evaluation session. The statistical analyses were carried out by using SAS version 9.0 statistics software (SAS Institute, Inc., Cary, NC).
Cell culture and lentiviral infection
Bladder cancer cell lines T24, UM-UC-3, 5637, J82 and RT-4 were purchased from the American Type Culture Collection. UM-UC-3 and T24 cells were grown in Dulbecco's modified Eagle's medium. 5637, J82 and RT-4 cells were maintained in RPMI 1640 with 10% fetal bovine serum and 1% (v/v) penicillin and streptomycin (100 μg/ml) and maintained at 37°C in a 5% CO2 atmosphere. The infection of lentivirus of Pim-1 siRNA was carried out as reported previously .
Western blot was performed as described previously . Briefly, the equal amounts of sample were resolved on a SDS polyacrylamide gel and transferred to a polyvinylidene difluoride membrane. Blots were incubated with the indicated primary antibodies overnight at 4°C and followed by detection with horseradish peroxidase-conjugated secondary antibody. The monoclonal anti-Pim-1 antibody was used at the dilution of 1:300, whereas anti-tubulin, Bcl-2, Bad and p-Bad (Ser112) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used at the dilution of 1:2,000.
Cell immunoperoxidase staining
Bladder cancer cells were plated onto the glass slides. After 24 h, cells were fixed with ice-cold acetone. The endogenous peroxides activity was inactivated by incubating cells with 0.03% H2O2 for 10 min. Slides were then incubated with Pim-1 antibody at room temperature for 1 hour and followed by horseradish peroxides-conjugated anti-mouse Ig (Chemicon; 1:500 dilutions). Finally, slides were incubated with biotin-labeled anti-IgG avidin-biotin peroxidase complex and developed with DAB Solution.
Colony formation assay
The cells (1 × 104) were seeded in 6-well plate and infected with the lentivirus expressing control siRNA or Pim-1 siRNA. Cell culture was maintained in complete medium for two weeks. The cell colonies were then visualized by Coomassie blue staining.
Cells were infected with lentivirus encoding control siRNA or Pim-1 siRNA. At 48 h post-infection, cells were seeded on 96-well plate at a density of 6 × 103 cells/well. After 24 h, cells were treated with various doses of Doxorubicin or Docetaxel (Sigma, St Louis, MO, USA) for another 48 h. The cells viability was measured by the WST-1 (Roche) assay following the manufacturer's instructions.
Overexpression of Pim-1 in human bladder cancer specimens
Pim-1 immunostaining intensity in human normal and maligancy bladder tissues
Pim-1 immunostaining intensity in No-invasive and Invasive bladder tumors
Expression profile of Pim-1 in bladder cancer cell lines
The localization of Pim-1 in bladder cancer cells was confirmed by immunoperoxidase staining and as the results showed that Pim-1 was detected in all human bladder cell lines examined, including T24, UM-UC-3, 5637, J82 and RT-4. Representative images are presented in Figure 2B. The positive signals were primarily immunolocalized in both cell cytoplasm and nucleus, while some cell membrane staining is also detected.
Pim-1 is essential for bladder cancer cell survival
Knockdown of Pim-1 sensitizes bladder cancer cells to chemotherapy in vitro
As Pim-1 is involved in drug resistance in some cancer types and adjuvant intravesical chemotherapy is one of the most common treatments in bladder cancer, we tested whether Pim-1 is also involved in drug response of bladder cancer cells. T24 and UM-UC-3 cells were treated with lentivirus encoding the siRNA specific for vector control or Pim-1 and then were tested for their responses to chemotherapeutic drugs. As shown in Figure 3C, downregulation of Pim-1 sensitized T24 and UM-UC-3 cells to Doxorubicin (DOX) and Docetaxel (DTX) when compared to the vector control. Our data implied that Pim-1 may contribute to the resistance of apoptosis and survival of bladder cancer cells in response to cytotoxic drugs.
In the present study we demonstrated for the first time that, Pim-1 was increased in human bladder cancer epithelium as compared with that in normal bladder tissue. When the tumors were stratified by Non-invasive and invasive, a statistically significant increase of Pim-1 expression was found in the subgroup of invasive tumor when compared with that in the Non-invasive tumor. Pim-1 was also detected in all human bladder cancer cell lines tested in our study. Knockdown Pim-1 led to decreased phosphorylation of Bad and reduced expression of Bcl-2. Furthermore, downregulation of Pim-1 inhibited the bladder cancer cells growth and sensitized them to chemotherapy in vitro. Further evaluation of the prognostic significance of Pim-1 in a larger cohort with sufficient follow-up times will allow better understand of the clinical significance of Pim-1.
Overexpression of the Pim-1 protein has been reported in hematolymphoid malignancies and solid cancers [4, 5]. Pim-1 has been asserted to promote tumorigenesis through multiple mechanisms, including its interaction with other proteins such as c-myc, p27KIP1, p21Cip1/WAF1, Bad, Cdc25A/C dual specificity phosphates, androgen receptors and its ability to induce genomic instability [19–22]. The oncogenic effect of Pim-1 on non-haematopoietic malignancies is currently under investigation. Ellwood-Yen et al demonstrated that the overexpression of Pim-1, in cooperation with increased levels of c-myc, could lead to murine prostatic intraepithelial neoplasia and invasive adenocarcinoma in c-myc transgenic mice . Taking into account the biological role of Pim-1 as an oncoprotein involved in cell cycle regulation and proliferative processes, our results suggested possible implication of Pim-1 in the initiation of bladder carcinogenesis. Moreover, upregulation of Pim-1 in invasive bladder cancer compared with Non-invasive tumors indicated that Pim-1 also may also contribute to bladder cancer progression.
Pim-1 has been considered as a survival kinase. Inhibition of Pim-1 results in a significant growth repression of prostate cancer cell . Several inhibitors of Pim-1 have been shown to inhibit the growth of cancer cells, such as leukemic cells as well as prostate cancer cells. There are clinical trials to explore the safety of one of the Pim-1 inhibitor, SGI-1776, for the treatment of refractory non-Hodgkin's lymphoma and prostate cancer [25, 26]. It also has been demonstrated that Pim-1 monoclonal antibody (mAb) could induce apoptosis in cancers cells of the prostate, breast and colon. Furthermore, the inhibition of Pim-1 function by treatment with Pim-1 siRNA, Pim-1 inhibitors or Pim-1 mAb sensitizes cancer cells to chemotherapy [15, 27–29]. It is noteworthy that Pim-1 interacted and phosphorylated Bad, Etk and BCRP leading to antagonism of drug-induced apoptosis [14, 17, 18]. In bladder cancer, after an initial transurethral resection of bladder tumor (TURBT), adjuvant intravesical therapy is another treatment strategy used to reduce the risk of recurrence. However, the cancer recurrence rate is still high and the recurring cancer cells can become more resistant to further intravesical chemotherapy. It is necessary to identify an effective strategy to counter act challenges associated with clinical management of bladder cancer patients. In this regard, Pim-1 might be one of the potential therapeutic targets for the treatment of bladder cancer and further studies examining Pim-1 as a target of therapeutics are worthy of investigation.
To the best of our knowledge, this is the first report showing overexpression of Pim-1 in bladder cancer and its association with bladder cancer cell survival, drug resistance and tumor progression. The current study offers significant information on the role and functions of Pim-1 in bladder cancer, and may aid in the development of novel therapy.
We would like to thank Dr Qiu (University of Maryland) for supplying the necessary experimental material (such as lentivirus of Pim-1 siRNA). This work was supported by grants from the National Natural Science Foundation(30872584); Guangdong Natural Science Foundation (8251008901000018); Doctoral Program of Guangdong Natural Science Foundation (9451008901002062), Preceptorial Program of Higher Education (20090171120062), Preceptorial Program of Sun Yat-Sen University (2009038) and International program fund of 985 project of Sun Yat-Sen University, China.
- Epstein JI, Amin MB, Reuter VR, Mostofi FK: The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998, 22 (12): 1435-1448. 10.1097/00000478-199812000-00001.View ArticleGoogle Scholar
- Edwards BK, Ward E, Kohler BA, et al: Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010, 116 (3): 544-573. 10.1002/cncr.24760.View ArticleGoogle Scholar
- Jemal A, Siegel R, Xu J, Ward E: Cancer statistics 2010. CA Cancer J Clin. 2010, 60 (5): 277-300. 10.3322/caac.20073.View ArticleGoogle Scholar
- Meeker TC, Nagarajan L, ar-Rushdi A, Croce CM: Cloning and characterization of the human PIM-1 gene: a putative oncogene related to the protein kinases. J Cell Biochem. 1987, 35 (2): 105-112. 10.1002/jcb.240350204.View ArticleGoogle Scholar
- Dhanasekaran SM, Barrette TR, Ghosh D, et al: Delineation of prognostic biomarkers in prostate cancer. Nature. 2001, 412 (6849): 822-826. 10.1038/35090585.View ArticleGoogle Scholar
- Chiang WF, Yen CY, Lin CN, et al: Up-regulation of a serine-threonine kinase proto-oncogene Pim-1 in oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2006, 35 (8): 740-745. 10.1016/j.ijom.2006.01.027.View ArticleGoogle Scholar
- Warnecke-Eberz U, Bollschweiler E, Drebber U, et al: Prognostic impact of protein overexpression of the proto-oncogene PIM-1 in gastric cancer. Anticancer Res. 2009, 29 (11): 4451-4455.Google Scholar
- Shah N, Pang B, Yeoh KG, et al: Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal. Eur J Cancer. 2008, 44 (15): 2144-2151. 10.1016/j.ejca.2008.06.044.View ArticleGoogle Scholar
- Mochizuki T, Kitanaka C, Noguchi K, Muramatsu T, Asai A, Kuchino Y: Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem. 1999, 274 (26): 18659-18666. 10.1074/jbc.274.26.18659.View ArticleGoogle Scholar
- Bhattacharya N, Wang Z, Davitt C, McKenzie IF, Xing PX, Magnuson NS: Pim-1 associates with protein complexes necessary for mitosis. Chromosoma. 2002, 111 (2): 80-95. 10.1007/s00412-002-0192-6.View ArticleGoogle Scholar
- Leverson JD, Koskinen PJ, Orrico FC, et al: Pim-1 kinase and p100 cooperate to enhance c-Myb activity. Mol Cell. 1998, 2 (4): 417-425. 10.1016/S1097-2765(00)80141-0.View ArticleGoogle Scholar
- Lilly M, Sandholm J, Cooper JJ, Koskinen PJ, Kraft A: The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway. Oncogene. 1999, 18 (27): 4022-4031. 10.1038/sj.onc.1202741.View ArticleGoogle Scholar
- Yan B, Zemskova M, Holder S, et al: The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem. 2003, 278 (46): 45358-45367. 10.1074/jbc.M307933200.View ArticleGoogle Scholar
- Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ: Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett. 2004, 571 (1-3): 43-49. 10.1016/j.febslet.2004.06.050.View ArticleGoogle Scholar
- Kim O, Jiang T, Xie Y, Guo Z, Chen H, Qiu Y: Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells. Oncogene. 2004, 23 (10): 1838-1844. 10.1038/sj.onc.1207304.View ArticleGoogle Scholar
- Cao KY, Mao XP, Wang DH, et al: High expression of PSM-E correlated with tumor grade in prostate cancer: a new alternatively spliced variant of prostate-specific membrane antigen. Prostate. 2007, 67 (16): 1791-1800. 10.1002/pros.20664.View ArticleGoogle Scholar
- Xie Y, Xu K, Dai B, et al: The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs. Oncogene. 2006, 25 (1): 70-78.Google Scholar
- Xie Y, Xu K, Linn DE, et al: The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J Biol Chem. 2008, 283 (6): 3349-3356. 10.1074/jbc.M707773200.View ArticleGoogle Scholar
- Zhang Y, Wang Z, Magnuson NS: Pim-1 kinase-dependent phosphorylation of p21Cip1/WAF1 regulates its stability and cellular localization in H1299 cells. Mol Cancer Res. 2007, 5 (9): 909-922. 10.1158/1541-7786.MCR-06-0388.View ArticleGoogle Scholar
- Morishita D, Katayama R, Sekimizu K, Tsuruo T, Fujita N: Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res. 2008, 68 (13): 5076-5085. 10.1158/0008-5472.CAN-08-0634.View ArticleGoogle Scholar
- Bachmann M, Kosan C, Xing PX, Montenarh M, Hoffmann I, Moroy T: The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C. Int J Biochem Cell Biol. 2006, 38 (3): 430-443. 10.1016/j.biocel.2005.10.010.View ArticleGoogle Scholar
- Wang J, Kim J, Roh M, et al: Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene. 2010, 29 (17): 2477-2487. 10.1038/onc.2010.10.View ArticleGoogle Scholar
- Ellwood-Yen K, Graeber TG, Wongvipat J, et al: Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell. 2003, 4 (3): 223-238. 10.1016/S1535-6108(03)00197-1.View ArticleGoogle Scholar
- Zhang T, Zhang X, Ding K, Yang K, Zhang Z, Xu Y: PIM-1 gene RNA interference induces growth inhibition and apoptosis of prostate cancer cells and suppresses tumor progression in vivo. J Surg Oncol. 2010, 101 (6): 513-519.Google Scholar
- Chen LS, Redkar S, Bearss D, Wierda WG, Gandhi V: Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2009, 114 (19): 4150-4157. 10.1182/blood-2009-03-212852.View ArticleGoogle Scholar
- Mumenthaler SM, Ng PY, Hodge A, et al: Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Ther. 2009, 8 (10): 2882-2893. 10.1158/1535-7163.MCT-09-0293.View ArticleGoogle Scholar
- Li J, Hu XF, Xing PX: Pim-1 expression and monoclonal antibody targeting in human leukemia cell lines. Exp Hematol. 2009, 37 (11): 1284-1294. 10.1016/j.exphem.2009.08.002.View ArticleGoogle Scholar
- Hu XF, Li J, Vandervalk S, Wang Z, Magnuson NS, Xing PX: PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis. J Clin Invest. 2009, 119 (2): 362-375.Google Scholar
- Teh BG: [Pim-1 induced by hypoxia is involved in drug resistance and tumorigenesis of solid tumor cells]. Hokkaido Igaku Zasshi. 2004, 79 (1): 19-26.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.